Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Read the full profile here.
Breakout Swing Trading Idea
Last earnings: 2022-08-02
Next earnings: 2022-10-26
Disclaimer: These trading ideas are merely to demonstrate what ChartMill is capable of and shows some typical results of a breakout filter. It is in no way actual financial advise to invest or trade in these stocks. The author has no pre-existing position in any of these stocks.
These two biopharma stocks aren't exciting growth plays, but they are reliable income vehicles.
Viking Therapeutics stock might in the midst of a historic run.
NuCana (NCNA) lost ~36% on Monday after an EU panel invalidated its patent related to sofosbuvir, Gilead’s (GILD) FDA-approved Hepatitis C therapy. Read more here.
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it.
California-based immune-oncology company Pionyr Immunotherapeutics announced Thursday that Gilead (GILD) has agreed to waive an exclusive option to acquire it. Read the full story here.
These stocks are all trading at less than 12 times their future profits.
By Julian Richard, Benzinga
Kite, a unit of Gilead Sciences (GILD), said that phase 3 data on its CAR-T therapy Yescarta demonstrated a significant improvement in overall survival compared to standard treatment...
Gamida Cell (GMDA) on Monday announced the resignation of chairman Robert Blum and the appointment of Shawn Cline Tomasello as chairwoman, effective immediately.
In line with a 2019 agreement, Gilead (GILD) has exercised its option to exclusively license an investigational protein degrader from Nurix Therapeutics (NRIX). Read the full story here.